Dabigatran etexilate - A novel oral anticoagulant for bleeding complications
Thromboembolic disease is a common cause of morbidity and mortality. Thrombin plays a key role in thrombotic events and thrombin inhibition represents a therapeutic event for thromboembolic events and has been identified as a target of therapy of its pivotal role in coagulation process. Anticoagulat...
Main Authors: | Himabindu Reddy, Chakka Gopinath, Mohamed Saleem Thattakudian Sheikuduman |
---|---|
Format: | Article |
Language: | English |
Published: |
Mazandaran University of Medical Sciences
2015-09-01
|
Series: | Pharmaceutical and Biomedical Research |
Subjects: | |
Online Access: | http://pbr.mazums.ac.ir/browse.php?a_code=A-10-26-20&slc_lang=en&sid=1 |
Similar Items
-
The Discovery of Dabigatran Etexilate
by: Joanne evan Ryn, et al.
Published: (2013-02-01) -
Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran
by: Jong-Min Kim, et al.
Published: (2022-01-01) -
Effects of direct oral anticoagulants dabigatran and rivaroxaban on the blood coagulation function in rabbits
by: Yin Lu, et al.
Published: (2022-01-01) -
Dabigatran etexilate: a direct thrombin inhibitor
by: M. Dugnani
Published: (2013-05-01) -
Dabigatran etexilate, a novel oral direct thrombin inhibitor, for preventing thromboembolic events after knee replacement arthroplasty
by: Moghtadaee M, et al.
Published: (2012-02-01)